Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.
There was neither a difference in the (low) percentage of only harmless side-reactions nor in the rate of sero-conversions (between 95-100%), when groups of 15 to 24 months old children were vaccinated either with the single components or with a combined MMR + Chickenpox-vaccine of a high potency.
D000914:Antibodies, Viral / Q000096:biosynthesis*; D019433:Chickenpox Vaccine; D002675:Child, Preschool; D004338:Drug Combinations / Q000276:immunology; D014645:Herpesvirus 3, Human / Q000276:immunology; D006801:Humans; D007117:Immunization, Secondary; D007223:Infant; D008458:Measles Vaccine / Q000276:immunology*; D008459:Measles virus / Q000276:immunology; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine / Q000276:immunology*; D009109:Mumps virus / Q000276:immunology; D012411:Rubella Vaccine / Q000276:immunology*; D012412:Rubella virus / Q000276:immunology; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology; D017778:Vaccines, Combined; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D019433:Chickenpox Vaccine; D004338:Drug Combinations; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined; D014765:Viral Vaccines; C050102:measles, mumps, rubella, varicella vaccine; C040901:rubella antibodies